Potentiation of cytotoxicity against a CEA positive cell line by the bispecific antibody OH1 using LAK cells from cancer-bearing patients

Oncology Reports

Volumn 5, Issue 5, 1998, Pages 1141-1146

  Baba, Miki ^a   Hideshima, Thru ^a   Yamashita, Yuichi ^a   Shirakusa, Takayuki ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Bispecific antibody; Carcinoembryonic antigen; CD3; Cytotoxicity; Lymphokine activated killer cell

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; BINDING SITE; CANCER CELL; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; TARGET CELL; TUMOR XENOGRAFT;

EID: 0031875375     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.5.1141     Document Type: Article

References (36)

1. Knuth A, Wölfel T, Meyer Zum Büschenfelde K-H: T cell response to human malignant tumors. Cancer Surv 13: 39-52, 1991.
2. Lotzová E: Role of interleukin-2 activated MHC-nonrestricted lymphocytes in antileukemia activity and therapy. Leuk Lymphoma 7: 15-28, 1992.
3. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987.
4. Rosenberg SA, Lotze MT and Mule JJ: New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 108: 853-864, 1988.
5. Songsivilai S and Lachmann PJ: Bispecific antibody: a tool for diagnosis and treatment of disease. Clin Exp Immunol 79: 315-321, 1990.
6. Bolhuis RLH, Sturm E and Braakman E: T cell targeting in cancer therapy. Cancer Immunol Immunther 34; 1-8, 1991.
7. Perez P, Titus JA, Lotze MT, Cuttitta F, Longo DL, Groves ES, Rabin H, Durda PJ and Segal DM: Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J Immunol 137: 2069-2072, 1986.
8. Nelson H, McKean DJ, Kerr LA and Donohue JH: Anti-tumor x anti-CD3 heteroconjugates direct human peripheral blood lymphocytes to lyse colon tumor cells. J Surg Res 48: 284-290, 1990.
9. Titus JA, Garrido MA, Hecht TT, Winkler DF, Wunderlich JR and Segal DM: Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. J Immunol 138: 4018-4022, 1987.
10. Barr IG, Miescher S, von Fliedner V, Buchegger F, Barras C, Lanzavecchia A, Mach JP and Carrel S: In vivo localization of a bispecific antibody which targets human T lymphocytes to lyse human colon cancer cells. Int J Cancer 43: 501-507, 1989.
11. Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM and Wunderlich JR: Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice. Cancer Res 50: 4227-4232, 1990.
12. Weiner GJ and Hillstrom JR: Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 147: 4035-4044, 1991.
13. Weiner GJ: Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice. Int J Cancer 7 (Suppl.): 63-66, 1992.
14. Shalaby MR, Carter P, Maneval D, Giltinan D and Kotts C: Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice. Clin Immunol Immunopathol 74: 185-192, 1995.
15. Bakács T, Lee J, Moreno MB, Zacharchuk CM, Cole MS, Yun Tso J, Paik CH, Ward JM and Segal DM: A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma. Int Immunol 7: 947-955, 1995.
16. Hideshima T, Iwasaki A, Baba M, Yamashita Y and Shirakusa T: The induction of cytotoxicity by a bispecific antibody against CEA positive cell line, in vivo. Surg Today 26: 83-88, 1996.
17. Okada H, Momota H, Azuma T, Hattori T and Okada N: Specific cytolysis of HIV-infected cells by lymphocytes armed with bifunctional antibodies. Immunol Lett 31: 247-252, 1992.
18. Okada H, Momota H, Okada N, Okamoto T and Azuma T: Elimination of HIV-infected cells by lymphocytes armed with a bifunctional antibody to gp120 of HIV and CD3. Immunol Lett 38: 195-199, 1993.
19. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CAY, Custer MC and Rosenberg SA: In vivo administration of purified human interleukin 2, II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL2. J Immunol 135: 2865-2875, 1985.
20. Adler A, Chervenick PA, Whiteside TL, Lotzova E and Herberman RB: Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71: 709-716, 1988.
21. Nitta T, Sato K, Okumura K and Ishii S: Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells. J Neurosurg 72: 476-481, 1990.
22. Nitta T, Sato K, Yagita H, Okumura K and Ishii S: Preliminary trial of specific taraeting therapy against malignant glioma. Lancet 335: 368-371, 1990.
23. Bolhuis RLH, Lamers CHJ, Goey SH, Eggermont AMM, Trimbos JBMZ, Stoter G, Lanzavecchia A, Di Re E, Miotti S, Raspagliesi F, Rivoltini L and Colnaghi MI: Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer 7 (Suppl.): 78-81, 1992.
24. Kaneko T, Fusauchi Y, Kakui Y, Masuda M, Akahoshi M, Teramura M, Motoji T, Okumura K, Mizoguchi H and Oshimi K: A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells. Blood 81: 1333-1341, 1993.
25. Kroesen BJ, ter Haar A, Spakman H, Willemse P, Sleijfer DTh, De Vrise EGE, Mulder NH, Berendsen HH, Limburg PC, The TH and De Leij L: Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother 37: 400-407, 1993.
26. Kroesen BJ, Buter J, Sleijfer DTh, Janssen RAJ, van der Graaf WTA, The TH, De Leij L and Mulder NH: Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 70: 652-661, 1994.
27. Urba WJ, Ewel C, Kopp W, Smith II JW, Steis RG, Ashwell JD, Creekmore SP, Rossio J, Sznol M, Sharfman W, Fenton R, Janik J, Watson T, Beveridge J and Longo DL: Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumor: a phase IA/B study. Cancer Res 52: 2394-2401, 1992.
28. Blank-Voorthuis CJAC, Braakman E, Ronteltap CPM, Tilly BC, Sturm E, Warnaar SO and Bolhuis RLH: Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. J Immunol 151: 2904-2914, 1993.
29. + T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol Immunother 39: 391-396, 1994.
30. Csóka M, Strauss G, Debatin K-M and Moldenhauer G: Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3 x CD19 bispecific antibody. Leukemia 10: 1765-1772, 1996.
31. Jacobs N, Griemers R, Mazzoni A, Trebak M, Schaaf-Lafontaine N, Boniver J and Moutschen MP: Further characterization of cytotoxic T cells generated by short-term culture of human peripheral blood lymphocytes with interleukin-2 and anti-CD3 mAb. Cancer Immunol Immunother 42: 369-375, 1996.
32. Bosslet K, Steinsträsser A, Schwarz A, Harthus HP, Lüben G, Kuhlmann L and Sedlacek HH: Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas. Eur J Nucl Med 14: 523-528, 1988.
33. 111In-labeled anti-CEA monoclonal antibody. Am J Roentgenol 151: 697-703, 1988.
34. Baum RP, Driever PH, Drahovsky D and Hör G: A rapid method for the determination of human CEA/mouse anti-CEA immune complexes in patients undergoing immunoscintigraphy. Eur J Nucl Med 15: 321-325, 1989.
35. Shakey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, Siegel JA, Wong GY, Gascccon P, Izon DO, Vezza M, Burger K, Swayne LC, Pinsky CM and Hansen HJ: Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 71: 2082-2096, 1993.
36. Murakami M, Kuroki M, Arakawa F, Haruno M, Kuwahara M, Ozaki H, Senba T and Matsuoka Y: Binding reactivity of monoclonal anti-carcinoembryonic antigen (CEA) antibodies with cell membrane-bound CEA and with free CEA in solution. Immunol Invest 25: 23-35, 1996.